AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17171865 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA applied 60 minutes prior to cannulation
Number of subjects: 3
Study 17171865 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% infiltration performed immediately prior to the procedure
Number of subjects: 3
Study 30614275 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 13287
Study 30614275 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 13287
Study 27720981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinised 0.75% ropivacaine-2% mepivacaine solution (pH 7.0)
Number of subjects: 40
Study 27720981 — intervention group
Group type: COMPARATOR
Intervention: Standard local anaesthetic solution (0.75% ropivacaine 5ml and 2% mepivacaine 5ml, pH 5.9)
Number of subjects: 40
Study 26360446 — intervention group
Group type: EXPERIMENTAL
Intervention: REFOCUS intervention (usual treatment plus REFOCUS)
Number of subjects: 403
Study 26360446 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment alone)
Number of subjects: 403
Study 23833853 — intervention group
Group type: EXPERIMENTAL
Intervention: Proseal LMA (PLMA)
Number of subjects: 200
Study 23833853 — intervention group
Group type: COMPARATOR
Intervention: Classic LMA (cLMA)
Number of subjects: 200
Study 21875240 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic‐Interpersonal Psychotherapy (GPIP)
Number of subjects: 0
Study 21875240 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 0
Study 19286579 — intervention group
Group type: EXPERIMENTAL
Intervention: PNS+tDCS
Number of subjects: 9
Study 17886373 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinoleukin added to regular treatment
Number of subjects: 161
Study 17886373 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment alone
Number of subjects: 161
Study 15884317 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive
Number of subjects: 80
Study 15884317 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etching adhesive
Number of subjects: 80
Study 15884317 — intervention group
Group type: COMPARATOR
Intervention: Caries-affected dentin
Number of subjects: 80
Study 15884317 — intervention group
Group type: COMPARATOR
Intervention: Intact dentin
Number of subjects: 80
Study 11206236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI), 400 microg once daily in the morning (AM)
Number of subjects: 286
Study 11206236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg once daily in the evening (PM)
Number of subjects: 286
Study 11206236 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg twice daily
Number of subjects: 286
Study 11206236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 9648990 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Crohn's disease
Number of subjects: 55
Study 9648990 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis
Number of subjects: 55
Study 9648990 — intervention group
Group type: COMPARATOR
Intervention: Inactive disease
Number of subjects: 55
Study 9648990 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease with fistulas
Number of subjects: 55
Study 8010269 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 66
Study 8010269 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with microadenomas
Number of subjects: 66
Study 2700641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush A (4.5 bristles per mm2)
Number of subjects: 90
Study 2700641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush B (8.3 bristles per mm2)
Number of subjects: 90
Study 2700641 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush C (11.8 bristles per mm2)
Number of subjects: 90
Study 786353 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (Sectral) 300 mg
Number of subjects: 10
Study 786353 — intervention group
Group type: EXPERIMENTAL
Intervention: practolol (Eraldin) 300 mg
Number of subjects: 10
Study 786353 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31981921 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intravenous co-amoxiclav
Number of subjects: 60
Study 31981921 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 60
Study 29224236 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 0
Study 29224236 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 29224236 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected cases
Number of subjects: 0
Study 29224236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases detected outside screening
Number of subjects: 0
Study 29224236 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced disease
Number of subjects: 0
Study 29224236 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary treatment
Number of subjects: 0
Study 28673611 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved-walking training (CWT)
Number of subjects: 24
Study 28673611 — intervention group
Group type: COMPARATOR
Intervention: Control exercise (CE)
Number of subjects: 24
Study 26657844 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 0
Study 26657844 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI) for males aged 75 years and above
Number of subjects: 0
Study 26657844 — intervention group
Group type: COMPARATOR
Intervention: Usual post-discharge care (control)
Number of subjects: 0
Study 23370069 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM) collaborative care intervention (cognitive‐behavioral therapy and/or medication)
Number of subjects: 1004
Study 23370069 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004
Study 23370069 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid medications in patients with comorbid major depression
Number of subjects: 1004
Study 23370069 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid medications in patients with pain
Number of subjects: 1004
Study 21514147 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/oxaliplatin (75 mg/m² on day 1 and 70 mg/m² on day 2 every 3 weeks)
Number of subjects: 50
Study 21514147 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (75 mg/m² on day 1 every 3 weeks)
Number of subjects: 50
Study 18451314 — intervention group
Group type: EXPERIMENTAL
Intervention: tNSAIDs, glucocorticoids, or coxibs (any inhibitor) with NT-proBNP > or = 100 ng/L
Number of subjects: 433
Study 18451314 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxibs (alone or with tNSAIDs or glucocorticoids) with NT-proBNP > or = 100 ng/L
Number of subjects: 433
Study 18451314 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more antiinflammatory drugs with NT-proBNP > or = 100 ng/L
Number of subjects: 433
Study 18451314 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP <100 ng/L across all treatment groups
Number of subjects: 433
Study 17040253 — intervention group
Group type: COMPARATOR
Intervention: ICD therapy in male patients
Number of subjects: 5
Study 17040253 — intervention group
Group type: COMPARATOR
Intervention: ICD therapy in female patients
Number of subjects: 5
Study 17040253 — intervention group
Group type: COMPARATOR
Intervention: ICD therapy in male patients (excluding COMPANION trial)
Number of subjects: 5
Study 17040253 — intervention group
Group type: COMPARATOR
Intervention: ICD therapy in female patients (excluding COMPANION trial)
Number of subjects: 5
Study 12943944 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (clomipramine mean dose 145 mg and fluoxetine mean dose 27 mg)
Number of subjects: 0
Study 12943944 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenergic antidepressants (desipramine mean dose 200 mg and nortriptyline mean dose 100 mg)
Number of subjects: 0
Study 12943944 — intervention group
Group type: COMPARATOR
Intervention: Noradrenergic antidepressants
Number of subjects: 0
Study 12943944 — intervention group
Group type: COMPARATOR
Intervention: Serotonergic antidepressants
Number of subjects: 0
Study 9559790 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine exposure
Number of subjects: 82
Study 8582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23
Study 8582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 23
Study 2676559 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg)
Number of subjects: 16
Study 2676559 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (not specified)
Number of subjects: 16
Study 2676559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (not specified)
Number of subjects: 16
Study 756039 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium dialysis
Number of subjects: 0
Study 756039 — intervention group
Group type: COMPARATOR
Intervention: Standard, hyponatric dialysis
Number of subjects: 0
Study 30586701 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Number of subjects: 616
Study 28457231 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program delivered by multi-disciplinary teams
Number of subjects: 1360
Study 28457231 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care practitioners and consultant cardiologists
Number of subjects: 1360
Study 28457231 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 1360
Study 28457231 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1360
Study 24971677 — intervention group
Group type: EXPERIMENTAL
Intervention: EX: exercise 5 days/week for 40 min/session at moderate intensity
Number of subjects: 57
Study 24971677 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐rST: combination of EX and rST
Number of subjects: 57
Study 24971677 — intervention group
Group type: EXPERIMENTAL
Intervention: rST: reduce ST and increase nonexercise physical activity
Number of subjects: 57
Study 24971677 — intervention group
Group type: COMPARATOR
Intervention: CON: maintain behavior
Number of subjects: 57
Study 23176350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local and distal points for 4 weeks
Number of subjects: 112
Study 23176350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 112
Study 19236979 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training complemented with eye movement and visual awareness exercises
Number of subjects: 19
Study 19236979 — intervention group
Group type: COMPARATOR
Intervention: Balance training alone
Number of subjects: 19
Study 17321428 — intervention group
Group type: EXPERIMENTAL
Intervention: Olweus Bullying Prevention Program
Number of subjects: 10
Study 17321428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 15350231 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-help package (the Heart Manual) alongside standard hospital-based cardiac rehabilitation
Number of subjects: 0
Study 15350231 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 12066648 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam (Dispersalloy)
Number of subjects: 16
Study 12066648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam (AmalgamBond Plus adhesive system with high‐performance additive powder and Dispersalloy amalgam)
Number of subjects: 16
Study 12066648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded resin composite (Scotchbond Multi‐Purpose adhesive system and Z100 resin composite)
Number of subjects: 16
Study 12066648 — intervention group
Group type: COMPARATOR
Intervention: No support (control group)
Number of subjects: 16
Study 10326065 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct disclosure of BMD results to women
Number of subjects: 0
Study 10326065 — intervention group
Group type: COMPARATOR
Intervention: Control group (disclosure through GPs)
Number of subjects: 0
Study 7661161 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy: bismuth nitrate (4 x 375 mg) plus metronidazole (4 x 250 mg) and tetracycline (4 x 500 mg) daily for 2 wk and ranitidine (150 mg) for the first week and bismuth nitrate (4 x 375 mg) alone for a further 2 wk
Number of subjects: 144
Study 7661161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (2 x 40 mg) plus amoxycillin (4 x 500 mg) for 2 wk
Number of subjects: 144
Study 7661161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) plus amoxycillin (4 x 500 mg) and tinidazole (2 x 500 mg) for 2 wk
Number of subjects: 144
Study 2596423 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alternating slimming diet
Number of subjects: 27
Study 2596423 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous slimming diet
Number of subjects: 27
Study 87551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 99
Study 87551 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 99
Study 31099946 — intervention group
Group type: EXPERIMENTAL
Intervention: Control‐IQ AP system
Number of subjects: 48
Study 31099946 — intervention group
Group type: COMPARATOR
Intervention: RM‐SAP
Number of subjects: 48
Study 31099946 — intervention group
Group type: EXPERIMENTAL
Intervention: Control‐IQ AP system and RM‐SAP
Number of subjects: 48
Study 28741578 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1830
Study 25039582 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97
Study 25039582 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 97
Study 23656173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60‐min period for 5 days)
Number of subjects: 32
Study 23656173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Group A)
Number of subjects: 32
Study 23656173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B, same dosage and administration of normal saline as Group A)
Number of subjects: 32
Study 22248833 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1-AS03(A) adjuvanted formulations
Number of subjects: 400
Study 22248833 — intervention group
Group type: COMPARATOR
Intervention: H5N1-DIL nonadjuvanted formulations
Number of subjects: 400
Study 19193660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (1.6 g/meal) rich in n‐3 alpha‐linolenic acid (ALA)
Number of subjects: 102
Study 19193660 — intervention group
Group type: COMPARATOR
Intervention: Commercial complementary meals with corn oil (3.4 g/meal) rich in n‐6 linoleic acid (LA)
Number of subjects: 102
Study 17329271 — intervention group
Group type: EXPERIMENTAL
Intervention: Flomoxef sodium for 2 days (89 patients)
Number of subjects: 180
Study 17329271 — intervention group
Group type: COMPARATOR
Intervention: Flomoxef sodium for 5 days (91 patients)
Number of subjects: 180
Study 16527713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH)
Number of subjects: 72
Study 16527713 — intervention group
Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 72
Study 16527713 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVH in overweight patients
Number of subjects: 72
Study 16527713 — intervention group
Group type: COMPARATOR
Intervention: TLH in overweight patients
Number of subjects: 72
Study 16527713 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVH in obese patients
Number of subjects: 72
Study 16527713 — intervention group
Group type: COMPARATOR
Intervention: TLH in obese patients
Number of subjects: 72
Study 14738260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anti-D
Number of subjects: 23
Study 14738260 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 23
Study 10591382 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg of intra-arterial recombinant prourokinase (r-proUK) plus heparin
Number of subjects: 180
Study 10591382 — intervention group
Group type: COMPARATOR
Intervention: Heparin only (control)
Number of subjects: 180
Study 8708717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose leucovorin (FA) 500 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group A)
Number of subjects: 291
Study 8708717 — intervention group
Group type: COMPARATOR
Intervention: Low-dose leucovorin (FA) 20 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group B)
Number of subjects: 291
Study 1788750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PGE1 (60 mcg)
Number of subjects: 0
Study 1788750 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 6267643 — intervention group
Group type: COMPARATOR
Intervention: 8 mg of naloxone IV
Number of subjects: 14
Study 6267643 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of naloxone
Number of subjects: 14
Study 30932998 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset exudation detected in 92 eyes; 1 month before conversion, hyperreflective foci, pigment epithelial detachment, retinal pigment epithelial defects, and haze were present in the majority of eyes.
Number of subjects: 1097
Study 30932998 — intervention group
Group type: EXPERIMENTAL
Intervention: At the onset of exudation
Number of subjects: 1097
Study 30932998 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month before conversion
Number of subjects: 1097
Study 30280459 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg selenium/day as selenium-enriched yeast
Number of subjects: 491
Study 30280459 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg selenium/day as selenium-enriched yeast
Number of subjects: 491
Study 30280459 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg selenium/day as selenium-enriched yeast
Number of subjects: 491
Study 30280459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-yeast)
Number of subjects: 491
Study 27545511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen IR/ER 600 mg (formulation A)
Number of subjects: 302
Study 27545511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen IR/ER 600 mg (formulation B)
Number of subjects: 302
Study 27545511 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg
Number of subjects: 302
Study 27545511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 25599304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ketorolac
Number of subjects: 30
Study 25599304 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 23974250 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic foot group (n=57)
Number of subjects: 137
Study 23974250 — intervention group
Group type: COMPARATOR
Intervention: Diabetes group (n=49)
Number of subjects: 137
Study 20960019 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP (laparoscopic totally extraperitoneal)
Number of subjects: 128
Study 20960019 — intervention group
Group type: COMPARATOR
Intervention: LICHT (open tension‐free mesh repair)
Number of subjects: 128
Study 19248858 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage (apple juice)
Number of subjects: 40
Study 19248858 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food (apple)
Number of subjects: 40
Study 19248858 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid food (apple sauce)
Number of subjects: 40
Study 19248858 — intervention group
Group type: COMPARATOR
Intervention: Test day energy intake
Number of subjects: 40
Study 17201541 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat of social exclusion
Number of subjects: 6
Study 17201541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of negative evaluation (low)
Number of subjects: 6
Study 17201541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of negative evaluation (high)
Number of subjects: 6
Study 15545544 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 U of botulinum exotoxin A in 0.25 mL of preserved saline (2 U/0.1 mL)
Number of subjects: 10
Study 15545544 — intervention group
Group type: COMPARATOR
Intervention: 5 U of botulinum exotoxin A in 0.05 mL of preserved saline (2 U/0.02 mL)
Number of subjects: 10
Study 11319508 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol treatment per vaginam
Number of subjects: 20
Study 11319508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no estriol treatment)
Number of subjects: 20
Study 11319508 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 20
Study 9151148 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosulfane membrane (highly asymmetric hydrophobic polysulfone)
Number of subjects: 6
Study 9151148 — intervention group
Group type: EXPERIMENTAL
Intervention: PS600 membrane (moderately asymmetric and hydrophobic polysulfone)
Number of subjects: 6
Study 9151148 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69HF membrane (Polyacylonitrile)
Number of subjects: 6
Study 8043059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus surgery
Number of subjects: 60
Study 8043059 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study 3306494 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (20‐80 mg)
Number of subjects: 60
Study 3306494 — intervention group
Group type: COMPARATOR
Intervention: hydralazine (5 mg)
Number of subjects: 60
Study 3306494 — intervention group
Group type: COMPARATOR
Intervention: hydralazine
Number of subjects: 60
Study 3306494 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 60
Study 31337404 — intervention group
Group type: EXPERIMENTAL
Intervention: 4AT (scores 0-12; prespecified score of > 3 considered positive)
Number of subjects: 785
Study 31337404 — intervention group
Group type: COMPARATOR
Intervention: CAM (Confusion Assessment Method; scored positive or negative)
Number of subjects: 785
Study 26922436 — intervention group
Group type: EXPERIMENTAL
Intervention: Punica granatum var pleniflora mouthwash
Number of subjects: 80
Study 26922436 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.2%
Number of subjects: 80